Privi Q1 PAT up 44% YoY to ₹83 Cr as finance costs ease; revenue +19%, OPM slips
PAT +43.94% YoY · revenue +19.22% · margins expanding
₹666.22 Cr
+19.22% YoY
₹82.84 Cr
+43.94% YoY
12.16%
+2pp YoY
₹21.56
Privi Speciality Chemicals opened FY27 with consolidated revenue of ₹666.2 Cr, up 19.2% YoY but down 7.7% sequentially off a seasonally/operationally stronger Q4 (₹721.5 Cr). Consolidated net profit for the period rose 43.9% YoY to ₹82.8 Cr; on the owners' line it was ₹84.2 Cr, with wholly-owned subsidiaries posting a small combined loss that carried ₹1.4 Cr of negative non-controlling interest. EPS came in at ₹21.56 versus ₹15.85 a year ago. There were no exceptional items on either side, so the reported growth is also the underlying growth.
Q1 FY-2027 vs prior quarters
The profit jump ran well ahead of the topline because most of the gain sat below the operating line. Operating margin actually eased to ~22.9% from 23.6% a year ago and ~25.0% in Q4, as materials and power/fuel costs stayed heavy in this single-segment aroma-chemicals business. The bottom-line strength came instead from finance costs falling to ₹16.7 Cr from ₹23.7 Cr — evidence of continued deleveraging — plus a higher other income of ₹15.2 Cr (vs ₹9.0 Cr). Net margin therefore expanded to 12.4% from 10.1% YoY. The PAT beat is best read as financing- and other-income-led rather than operating-leverage-led.
The stock went into the print at ₹3,608.8, down 2% over the past month of trading.
Management guides for 20% revenue growth in the upcoming fiscal year, with a long-term target of INR 5,000 crore in revenue and INR 1,000 crore in EBITDA within 3-4 years. They expect to sustain robust EBITDA margins around 25%, supported by operational efficiencies and a richer product mix from new capacities and valu
— This quarter: met
The 19% topline broadly meets the ~20% FY27 revenue growth management guided on the May Q4 concall, and confirms the confident tone struck then — but Q1 EBITDA margin (~22.9%) runs below both the ~25% aspiration and FY26's 25.76%, leaving margin as the open question against guidance. No brokerage consensus for the quarter could be located, so the print cannot be scored against Street. Standalone tells the same story (PAT ₹84.3 Cr on revenue ₹600.6 Cr), so consolidated and standalone do not diverge materially. On the corporate side, the board has filed the NCLT scheme to amalgamate Privi Fine Sciences and Privi Biotechnologies (filed June 25, 2026) and recommended a ₹10/share FY26 final dividend; the AGM notice, annual-report dispatch and BRSR filing this quarter are routine.
W1
EBITDA/operating margin recovery toward the ~25% target — Q1 OPM ~22.9% vs FY26 25.76%
W2
Whether revenue holds the ~20% FY27 guidance after a −7.7% QoQ start (₹666.2 Cr)
W3
NCLT approval/completion of the amalgamation scheme (filed June 25, 2026) and phased capex commissioning
Clean digital PDF, headers unambiguous, statement in ₹ lakhs → converted to ₹ Cr. No exceptional items either period. Consolidated total net profit ₹82.84 Cr; owners' share ₹84.21 Cr as subsidiaries booked a small combined loss (NCI −₹1.37 Cr). OPM eased YoY even as NPM rose — a financing/other-income-led beat, not operating leverage.
Informational and educational content only. Not investment advice.